



Docket No. MCP-1  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
Weinshenker, N. M et al.


Serial No.: 10/659,501  
Filed: September 10, 2003

Group Art Unit: 1614  
Examiner: N/A

For: Cobalamin conjugates for anti-tumor therapy

Mail Stop IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 14, 2004.	
	(Typed or Printed Name)
	(Signature)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

The following sections are submitted for this Information Disclosure Statement:

1. X Preliminary Statements
2. X FORM PTO - 1449
3. \_\_\_ Statement As To Information Not Found in Patents or Publications
4. \_\_\_ Identification Of Prior Application In Which Information Was Cited And For Which No Copies Are Submitted Or Need Be Submitted
5. \_\_\_ Cumulative Patents or Publications
6. \_\_\_ Translation(s) of Non-English Language Documents
7. \_\_\_ Concise Explanation of Non-English Language Listed Information Items
8. \_\_\_ Copies of Listed Information Items Accompanying This Statement
9. X Identification of Person(s) Making This Information Disclosure Statement

Section 1. Preliminary Statements

Applicant submits herewith patents, publications or other information which may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 CFR 1.56(g)), or as an admission that the information cited is, or is considered to be, material to patentability.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner.

Section 2. FORM PTO - 1449

Form PTO - 1449 (2 sheets) is enclosed herewith.

Section 3. Statement As To Information Not Found In Patents Or Publications (Information not listed in PTO 1449)

Section 4. Identification Of Prior Application In Which Information Was Cited And for Which No Copies Are Submitted Or Need Be Submitted

This application relies, under 35 U.S.C. 120, on the earlier filing date of prior application S/N \_\_\_\_\_, filed on \_\_\_\_\_.

Section 5. Cumulative Patents or Publications

\_\_\_\_\_ is cumulative of the following patents or publications listed on Form PTO 1449:

---

---

---

In accordance with 37 CFR 1.98(c) a copy of only \_\_\_\_\_ is being submitted with this information disclosure statement.

Section 6. Translation(s) of Non-English Language Documents

- ☐ Submitted herewith is an English translation of the following foreign language patents, publications or information or of those portions of those patents, publications or information considered to be material.
- ☐ No English language translations of the foreign language patents, publications or information or parts thereof are readily available, except for those listed above.
- ☐ The following foreign language documents submitted are believed to be the equivalent or substantial equivalent of the English language documents identified below, which are also submitted herewith.

Section 7. Concise Explanation of Non-English Language Listed Information Items

Section 8. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

- ☐ Exception(s) to above
- ☐ Items in prior application from which an earlier filing date is claimed for this application as identified in Section 4.
- ☐ Cumulative patents or publications identified in Section 5.

Section 9. Identification of Person(s) Making This INFORMATION DISCLOSURE STATEMENT

The person making this statement is

- (a) ☐ the inventor(s) who signs below

\_\_\_\_\_  
Signature of Inventor

\_\_\_\_\_  
Typed name of inventor

- (b) ☒ the agent who signs below on the basis of:
- ☐ information supplied by the inventor(s)

information supplied by an individual associated with the filing and prosecution of this application (37 CFR 1.56(c))

  X   information in the agent's file

It is respectfully requested that the references identified in this Information Disclosure Statement be considered by the Examiner, be made a part of the official record, and be cited in the issued patent.

Date: \_\_\_\_\_

Innovar, L.L.C.

P.O. Box 250647

Plano, TX 75025

(972) 747-7373 ph.

(972) 747-7375 fax

Respectfully submitted,



Rick Matos

Registration No. 40,082

Agent for Applicants

Email: [innovarllc@sbcglobal.net](mailto:innovarllc@sbcglobal.net)

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/659,501
		Filing Date	09/10/2003
		First Named Inventor	Weinshenker, N. et al.
		Group Art Unit	1614
		Examiner Name	N/A
		Attorney Docket Number	MCP-1
Sheet	2	of	2

OTHER – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	2
	P	P.L. CARL ET AL.; "A novel connector linkage applicable in prodrug design"; J. Med. Chem. (1981), 24(5), pp.479-480.	
	Q	B.E. TOKI ET AL.; "Protease-mediated fragmentation of p-amidobenzyl ethers: A new strategy for the activation of anticancer drugs"; J. Org. Chem. (2002), 67(6), pp. 1866-1872.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--